Phase 2 Evaluation of Topotecan Administered on a 3-Day Schedule in the Treatment of Platinum- and Paclitaxel-Refractory Ovarian Cancer-Reference-Cited by-同舟云学术

Phase 2 Evaluation of Topotecan Administered on a 3-Day Schedule in the Treatment of Platinum- and Paclitaxel-Refractory Ovarian Cancer

Published:2000-10 Issue:1 Volume:79 Page:116-119
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Markman Maurie,Kennedy Alexander,Webster Kenneth,Kulp Barbara,Peterson Gertrude,Belinson Jerome

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference12 articles.

1. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer;McGuire;N Engl J Med,1996

2. Long-term follow-up of GOG-111: a randomized trial comparing cisplatin combined with cyclophosphamide or paclitaxel in patients with stage III or IV epithelial ovarian cancer;McGuire;Int J Gynecol Cancer,1999

3. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer;ten Bokkel Huinink;J Clin Oncol,1997

4. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel;Bookman;J Clin Oncol,1998

5. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma;Kudelka;J Clin Oncol,1996

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hidden in plain sight – Survival consequences of baseline symptom burden in women with recurrent ovarian cancer;Gynecologic Oncology;2024-06

2. Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer;Holland‐Frei Cancer Medicine;2022-10-21

3. Efficacy of non‑platinum chemotherapy in platinum‑resistant ovarian cancer: a meta‑analysis;Malignant tumours;2022-04-08

4. Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer;Holland-Frei Cancer Medicine;2017-02-26

5. Highlights of recent developments and trends in cancer nanotechnology research—View from NCI Alliance for Nanotechnology in Cancer;Biotechnology Advances;2014-07